Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
October 2018
-
Press Release
Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek… -
Press Release
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to… -
Story Discovery
Researchers boost understanding of T-cell therapy in blood cancer
Novartis investigators find genetic explanations for why some young patients relapse.
September 2018
-
Press Release
Novartis announces five grant recipients of eXcellence in Ophthalmology Vision Award (XOVA) for nonprofit sustainable eye health initiatives
A panel of independent ophthalmologists and optometrists selected five winners out of more than 100 entries from 34 countries The 2018 grants support initiatives ranging from training teachers… -
Press Release
Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness
In the Phase III RAINBOW study, despite marginally missing statistical significance for the primary endpoint of demonstrating superiority of Lucentis® to laser surgery, Lucentis was shown to be… -
Press Release
New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD
Pre-specified analysis provides insight into maintenance treatment effectiveness with like-for-like comparison of brolucizumab versus aflibercept over entire week 36 to 48 treatment period … -
Press Release
Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim
Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and qualitySandoz seeks approval in the… -
Press Release
Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe
Children and adolescents with multiple sclerosis (MS) experience more frequent and often more severe relapses than adults with the disease, hindering their development and ability to take part in… -
Press Release
Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease
If approved in expected timeframe, Luxturna* (voretigene neparvovec) will be first and only gene therapy available in EU to treat a rare inherited retinal disease Children and adults… -
Press Release
World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
From a sample of over 10,000 adults, 62% are worried that they may develop Alzheimer's disease and 91% believe the solution to tackling diseases lies in medical research[1] 79% are willing… -
Press Release
Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals
Alcon Experience Academy serves as umbrella for industry-leading training and educational resources for all eye care professionals New website houses a robust library of more than 500 videos,… -
Press Release
Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients
Real-world evidence confirms Cosentyx® efficacy and safety consistent with previously reported clinical studies[1]-[4] Novartis presents a large program of real-world evidence at the 27th…